Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively.
Medigene AG has selected its lead candidate for MDG-2011, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
Biontech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) have established a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT-166 for the prevention of mpox (formerly monkeypox).
Retinoic acid (RA) is fundamental to maintain immune homeostasis. In this process, RA induces regulatory T cells and promotes tolerance, but depending on the conditions, RA may also promote inflammation and tissue damage.
By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new insights into how amyloid plaques, tau tangles and neuronal death are related at the molecular level.
Shanghai SIMR Biotech Co. Ltd. has developed imidazopyridazine derivatives acting as GABA-A modulators and reported to be useful for the treatment of pain, Alzheimer’s disease, multi-infarct dementia, epilepsy, pruritus and stroke.
Research at Sunshine Lake Pharma Co. Ltd. has led to the identification of Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of multiple sclerosis, allergy, cancer, influenza, hepatitis B virus, hepatitis C virus, herpes virus, and HIV infections, among others.
Researchers at GSK plc have developed cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) consisting of a cell-surface protein targeting moiety (particularly, folate receptors) covalently linked to a moiety targeting an exogenous antibody (such as anti-cotinine antibody) through a linker.
Eisai R&D Management Co. Ltd., National Institutes for Quantum and Radiological Science and Technology (QST), Ono Pharmaceutical Co. Ltd. and Takeda Pharmaceutical Co. Ltd. have patented new radiolabeled compounds targeting α-synuclein (α-Syn, SNCA) and acting as optical imaging agents for the diagnosis of Lewy body dementia (DLB), multiple system atrophy and Parkinson’s disease.
Di-cyclopropyl based interleukin-17A (IL-17A) production inhibitors have been reported in a Dice Alpha Inc. patent as potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
RSS
